Background: Anti-TNF prevents postoperative Crohn's disease recurrence in most patients but not all. This study aimed to define the relationship between adalimumab pharmacokinetics, maintenance of remission and recurrence. Methods: As part of a study of postoperative Crohn's disease management, some patients undergoing resection received prophylactic postoperative adalimumab. In these patients, serum and fecal adalimumab concentration and serum anti-adalimumab antibodies [AAAs] 
Introduction
Adalimumab [Humira; AbbVie Laboratories, AbbVie Park, IL] is a subcutaneously administered, recombinant, fully humanized, immunoglobulin G1 monoclonal antibody that binds with high affinity and specificity to human TNF. Controlled trials have demonstrated safety and efficacy of adalimumab in the treatment of moderate to severe Crohn's disease for induction and maintenance of remission. [1] [2] [3] Although anti-TNF therapy is the most effective at preventing disease recurrence after intestinal resection, 4, 5 it is not always effective. The factors that cause some patients to have disease recurrence after surgery despite such therapy are unknown. Primary and secondary loss of response to anti-TNF drugs when treating established luminal disease is common, 6 but whether this applies in the postoperative setting, in which the disease burden is very low, is unknown.
A low serum concentration of adalimumab and the development of anti-adalimumab antibodies [AAAs] have been implicated in the development of adalimumab failure and poor clinical outcomes in Crohn's disease. 7, 8 When treating luminal disease, serum concentrations of adalimumab are higher in those achieving clinical remission and mucosal healing and have been found to be inversely associated with C-reactive protein, [8] [9] [10] although prospective data are lacking. In the Trough Level Adapted Infliximab Treatment [TAXIT] 11 trial, dose optimization of anti-TNF therapy to achieve "target" or optimal drug concentration increased the proportion of patients in clinical remission. In the maintenance phase of the study, anti-TNF therapeutic drug monitoring led to a reduction in the number of disease flares and reduction in C-reactive protein [CRP] .
Primary non-response or secondary loss of response are relatively easy to recognize in the setting of luminal disease. However, the nature of the disease-drug relationship in the postoperative setting, in which the starting point is absence of macroscopic disease, is unknown. Small studies to date examining this relationship have presented contradictory messages about the utility of therapeutic anti-TNF monitoring postoperatively. 12, 13 The most recent and largest study, a retrospective review of 73 anti-TNF patients treated postoperatively, found that lower IFX concentrations and presence of anti-infliximab [IFX] antibodies were associated with the likelihood of endoscopic recurrence postoperatively, but no such association was demonstrated for adalmimumab. 14 In a study of 6 patients on prophylactic adalimumab monotherapy, drug concentrations and AAAs in relation to endoscopic and clinical outcomes were assessed after intestinal resection in Crohn's disease. Bodini et al. 12 found that median adalimumab trough concentrations in patients with clinical or endoscopic recurrence were lower than in those who maintained remission, implying that measurement of adalimumab concentration and AAAs after surgery could be useful in reducing postoperative recurrence. 12 In another study of 5 patients on low-dose IFX, none experienced postoperative endoscopic recurrence one year following surgery, despite subtherapeutic IFX concentrations. 13 This study aimed to explore the relationship between adalimumab drug pharmacokinetics and disease course in the postoperative setting, when disease burden is usually low. We aimed to determine specifically whether postoperative Crohn's disease recurrence relates to low serum adalimumab concentration, with or without the development of antibodies to adalimumab.
The role of adalimumab pharmacokinetics in the recurrence of Crohn's disease after resection was prospectively studied by relating serum adalimumab and AAA concentrations to endoscopic disease recurrence, clinical recurrence as measured by the Crohn's disease activity index [CDAI] , the serum marker of inflammation CRP, the marker of early microscopic inflammation faecal calprotectin [FC] , smoking and BMI. This study also aimed to explore a possible role of faecal drug loss.
Methods

The clinical postoperative recurrence ["POCER"] study
The Post-Operative Crohn's Endoscopic Recurrence ["POCER"] study was a prospective randomized controlled trial that assessed the value of postoperative endoscopic assessment and treatment intensification for early mucosal recurrence. Patients were stratified according to risk of recurrence. Smokers, patients with perforating disease, or patients with ≥1 previous resection were classified as "high-risk"; all others were "low-risk". All patients underwent resection of all macroscopic disease and then received 3 months of metronidazole. High-risk patients also received daily azathioprine [ A final consensus score was determined by the 2 blinded assessors.
Adalimumab and anti-adalimumab antibody concentration measurements
Serum samples were taken at 6, 12 and 18 months postoperatively from patients receiving adalimumab for at least 6 months, according to when adalimumab was commenced postoperatively. Serum samples were taken irrespective of the timing of the last administered dose of adalimumab.
Samples were stored at -20°C until the conclusion of the clinical study, at which time all samples were analysed simultaneously. Adalimumab and AAA concentration measurements were performed by Prometheus Laboratories [San Diego, CA, USA], using a liquid-phase mobility shift assay. The threshold level for both adalimumab and AAA were defined as 1.65 SDs from the mean, obtained previously, of 100 samples from adalimumab-exposed participants [0.58 µg/mL for adalimumab and 1.7 U/mL for AAA].
Faecal adalimumab drug concentration
Stool samples were collected pre-operatively and at 6, 12 and 18 months after surgery. Samples were stored at -80°C until the conclusion of the clinical study, at which time all samples were analysed simultaneously.
Faecal adalimumab concentrations were measured in patients exposed to adalimumab postoperatively using a proprietary, sensitive, fluorescence-based immunoassay performed by Prometheus Laboratories. Detailed methodology is included in a supplementary document. 
Faecal calprotectin measurement
Stool samples were collected pre-operatively and at 6, 12 and 18 months after surgery. Samples were stored at -80°C until the conclusion of the clinical study, at which time all samples were analysed simultaneously. FC was measured by a quantitative enzyme immunoassay [fCAL TM , Bühlmann, Schonenbuch, Switzerland] as per the manufacturer's instructions, without knowledge of patient data. Concentrations were expressed as μg/g of stool.
The upper limit of the normal range of FC in patients without gut inflammation is well defined as 50 μg/g.
16 Faecal calprotectin > 100 μg/g is accurate for the diagnosis of postoperative endoscopic recurrence for patients with Crohn's disease. 17 ,18
Statistical analysis
Data were analysed using STATA12 [StataCorp, College Station, TX]. Associations between categorical data were assessed using either Chi-square or Fisher's exact test. Non-parametric comparison of continuous variables was performed using Wilcoxon rank sum. Associations between endoscopic disease and adalimumab titre, AAA, CDAI, CRP and FC were assessed by logistic regression analysis for binary outcomes and by the determination of Spearman's rank correlation coefficient [rho] for non-parametric correlations. Gamma regression was used to determine the predictors of the drug concentration at both 6 and 18 months. Smoking was analysed as a binary variable by comparing current with past and never smokers, and the reverse. Figure 1 . Of the 52 patients, 43 were in the active care arm and nine in the standard care arm. All patients in the active care arm had a colonoscopy at 6 months, and 40 of 43 had a colonoscopy at 18 months; 3 of the 43 had dropped out of the study between 6 and 18 months. In the standard care arm, all 9 patients had a colonoscopy at 18 months.
Results
Patient study disposition and patient demographics
Forty-three patients had an endoscopy at 6 months and 49 at 18 months. One hundred and twenty-five serum samples could be This likely reflects the fact that patients commenced on adalimumab immediately postoperatively [baseline] were on adalimumab monotherapy, whereas most patients commenced on adalimumab at 6 months were also on a thiopurine. The adalimumab concentration was significantly lower in patients on monotherapy (7.89 µg/mL [IQR 3.81-13.02]) compared with patients on combination therapy (11.725 µg/mL [IQR 8.45-16.38], p = 0.001) when samples from all available time points were considered [ Figure 4 ].
Twenty patients [39%] in this study were current smokers, compared with 32 who were non-smokers. Median adalimumab concentrations for these patients, across all time points, were Figure 5 ]. These differences were significant when all 4 groups were compared [p = 0.046].
Faecal adalimumab drug concentration
Of the 52 patients, 47 had faecal samples available for adalimumab concentration analysis. A total of 91 samples were collected at 6, 12 or 18 months postoperatively. All samples tested showed results below the lower limit of quantification. Figure S1 ]. If AAAs were detected, they persisted in all subsequent samples in all patients. In 11 of the 15 patients, AAAs developed within the first 6 months of commencing adalimumab.
Serum adalimumab concentration and endoscopic findings, CDAI, CRP and faecal calprotectin
Multivariate analysis
No association between endoscopic recurrence and adalimumab drug level was observed at 6 or 18 months when adjusted for the presence of AAAs, CRP or BMI. At 18 months, only the presence of AAAs and increasing BMI were significantly associated with a reduction in adalimumab drug concentration when adjusted for endoscopic recurrence and CRP. Those with detectable AAAs had a 92% lower serum adalimumab concentration [CI 42-143%, p < 0.001]. A 1-point increase in BMI led to a 5% reduction in serum adalimumab concentration [CI 0.5-9.4%, p = 0.028]. Detectable AAAs at 6 months influenced adalimumab drug concentration at 18 months, with these patients having a 98% lower drug concentration at 18 months [CI 41-155%], p = 0.001. No other factors at 6 months predicted drug concentration at 18 months.
Discussion
There is growing evidence that therapeutic drug monitoring of anti-TNF drugs and antibodies against anti-TNF drugs may guide therapeutic decision-making for Crohn's disease patients. 10 Higher concentrations of anti-TNF drugs are associated with better outcomes, including clinical remission and mucosal healing, in patients with active luminal disease. 20 Adalimumab serum drug concentrations associated with clinical remission in luminal Crohn's disease range from 3 to 5.85 µg/mL, 8, 10 with a sensitivity and specificity of 68% and 71%, respectively. A concentration cut-off of 8.1 µg/mL has been found in a retrospective study to best discriminate between mucosal healing and lack of healing, with a sensitivity and specificity of 91% and 76%, respectively. 9 In many of these studies, endoscopic disease burden is unknown and is likely to be a factor affecting drug concentration. This study assessed therapeutic drug monitoring in patients who had undergone surgical resection of all active intestinal Crohn's disease, providing a unique setting for the understanding of the effect of anti-TNF drug concentration on the development of disease. This study found that adalimumab drug concentrations did not correlate with endoscopic recurrence after Crohn's disease resection. A significant but weak correlation was seen between adalimumab drug concentration and FC, suggesting that higher anti-TNF concentrations are associated with less microscopic inflammation, a probable precursor to later macroscopic inflammation.
Three studies have previously examined anti-TNF drug titres in Crohn's disease patients postoperatively, with inconsistent results. 12, 13 In one study, 6 patients were treated with prophylactic adalimumab monotherapy after intestinal resection for Crohn's disease. Adalimumab trough concentration and AAAs were analysed with respect to endoscopic and clinical outcomes. Median adalimumab concentrations in patients with postoperative clinical or endoscopic recurrence were lower when compared with those who maintained remission (7.5 µg/mL [4.4-9.8 µg/mL] vs 13.9 µg/mL [8.9-23.6 µg/ mL], p < 0.01). 12 In the second study, 5 patients were treated with low-dose IFX [3mg/kg] postoperatively to prevent endoscopic recurrence. All patients remained in clinical and endoscopic remission for an average of 18 months following surgery, despite subtherapeutic IFX drug concentrations [mean ± SE 2.0 ± 0.3 µg/mL]. 13 In the third study, 73 patients [32 on IFX and 41 on adalimumab for postoperative prophylaxis] with anti-TNF drug monitoring data available were reviewed retrospectively. The need for dose optimization as well as trough IFX concentration and the presence of antibodies to IFX were significantly associated with postoperative endoscopic recurrence. The optimal IFX concentration for prediction of endoscopic recurrence was low, at 1.8μg/g, suggesting that low-dose treatment may be sufficient for sustaining endoscopic remission. Interestingly, in this study no such association was observed for adalimumabtreated patients where drug concentration or AAA development was not associated with endoscopic recurrence. 14 The recurrence of disease in the short to medium term, in the presence of satisfactory serum drug concentrations, may reflect non-drug responsiveness ["primary non-response"]. Alternatively, inflammatory mechanisms that predominate over TNF-mediated mechanisms may be important in those patients with early disease recurrence. The same is true of recurrence in the patients who smoke. In the longer term, it might be expected that secondary loss of response to prophylactic drug therapy may lead some patients to experience disease recurrence, in a situation analogous to the treatment of established luminal Crohn's disease.
The serum adalimumab concentration has been shown to be relatively constant when given at maintenance doses of 40 mg subcutaneously once per fortnight. 21, 22 This is due to a combination of low-dose subcutaneous administration of the drug and the long half-life of 10-20 days, with time to peak concentration of 6.5 days. 21 Although some studies examining the relationship between adalimumab drug concentration and clinical outcomes have only included trough concentrations, the pharmacokinetic profile of adalimumab suggests that serum measurement of drug concentration is accurate at any time during maintenance therapy, regardless of the timing of drug dosing. 21, 23, 24 Although associated with an increased risk of loss of response to anti-TNF treatment, 25 smoking has not been associated with a lower anti-TNF drug concentration. 26 Smoking in the POCER study was associated with a significantly increased risk of endoscopic recurrence. 4 In this study, there was no significant difference in drug concentration between smokers and non-smokers, suggesting that the mechanism by which smoking increases the risk of Crohn's disease recurring after surgery is not related to adalimumab pharmacokinetics.
The influence of BMI on adalimumab efficacy and drug concentration has been debated in the literature. BMI has been shown to be important in predicting adalimumab efficacy. 27 Patients with a higher BMI have been shown to be at increased risk of loss of response to adalimumab and are more likely to need dose escalation when compared with those with a lower BMI. 28 Studies in Crohn's disease patients have not shown a significant impact of BMI on drug pharmacokinetics to explain these clinical findings. 22, 26 However, recent data have shown a significantly lower serum adalimumab concentration in patients with a BMI of >30, compared with those with a BMI of <30. 29 Increased visceral adipose tissue has been associated with increased inflammation and poorer outcome in patients with inflammatory bowel disease and is a predictor of postoperative endoscopic recurrence in Crohn's disease. 30 In this study, antibodies to adalimumab were seen in one-quarter of patients and most commonly developed within the first 6 months of adalimumab treatment. The development of AAAs was not associated with higher rates of endoscopic recurrence compared with those without. Once detected, antibodies were persistent, not transient, and were associated with lower drug concentrations compared with when antibodies were not found. The presence of AAAs at 6 months predicted a dramatically lower drug concentration at 18 months. In most antibody-positive patients, however, the drug concentration remained within the therapeutic range. Antibody identification is therefore of uncertain significance. The development of AAAs has been reported in up to 44% of patients, but whether this rate is reduced by concomitant immunomodulator therapy is unclear. 7, 8, 31 The lower detection rate of AAAs in this study [28% of patients] may reflect the high incidence of combination therapy [38.5%] compared with in previous published studies, or the low number of patients with exposure to adalimumab prior to study entry. 7, 8 A novel aspect of this study was the assessment for the presence of faecal adalimumab. We aimed to establish whether faecal loss of adalimumab occurs in the postoperative setting, and the possible effect on serum drug concentration and clinical or endoscopic outcomes. Faecal adalimumab was not detected in any sample in this study. Most likely this relates to the small disease burden with localized recurrent inflammation. Faecal IFX loss has been described in acute severe ulcerative colitis, in association with a low serum drug concentration and lack of clinical response. 32 In the current study, disease was mild and localized to a small section of the intestine.
Limitations of this study include the relatively small sample size and the fact that serum samples were taken irrespective of the timing of the last administered dose of adalimumab.
In conclusion, lower drug concentrations soon after intestinal resection in patients on adalimumab therapy may not relate to endoscopic Crohn's disease recurrence. Mechanisms other than inadequate anti-TNF drug concentration are therefore likely to be important. The same is true of the increased recurrence related to smoking. The mechanistic cause of disease recurrence after surgery requires further research. 
